These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 30680599)

  • 1. Advances in Therapeutic Drug Monitoring for Small-Molecule and Biologic Therapies in Inflammatory Bowel Disease.
    Ma C; Battat R; Jairath V; Vande Casteele N
    Curr Treat Options Gastroenterol; 2019 Mar; 17(1):127-145. PubMed ID: 30680599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Drug Monitoring for Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease.
    Dutt K; Vasudevan A
    Medicina (Kaunas); 2024 Jan; 60(2):. PubMed ID: 38399538
    [No Abstract]   [Full Text] [Related]  

  • 3. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
    Papamichael K; Cheifetz AS; Melmed GY; Irving PM; Vande Casteele N; Kozuch PL; Raffals LE; Baidoo L; Bressler B; Devlin SM; Jones J; Kaplan GG; Sparrow MP; Velayos FS; Ullman T; Siegel CA
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1655-1668.e3. PubMed ID: 30928454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
    Carman N; Mack DR; Benchimol EI
    Curr Gastroenterol Rep; 2018 Apr; 20(5):18. PubMed ID: 29623442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Practical Guide to Therapeutic Drug Monitoring of Biologic Medications for Inflammatory Bowel Disease.
    Vaughn BP
    J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug?
    Papamichael K; Cheifetz AS
    Curr Opin Gastroenterol; 2019 Jul; 35(4):302-310. PubMed ID: 30973355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in Therapeutic Drug Monitoring in Biologic Therapies for Pediatric Inflammatory Bowel Disease.
    Kapoor A; Crowley E
    Front Pediatr; 2021; 9():661536. PubMed ID: 34123968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proactive Therapeutic Drug Monitoring Versus Conventional Management for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
    Nguyen NH; Solitano V; Vuyyuru SK; MacDonald JK; Syversen SW; Jørgensen KK; Crowley E; Ma C; Jairath V; Singh S
    Gastroenterology; 2022 Oct; 163(4):937-949.e2. PubMed ID: 35753383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives.
    Irving PM; Gecse KB
    Gastroenterology; 2022 Apr; 162(5):1512-1524. PubMed ID: 35167865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Drug Monitoring of Biologics for Patients with Inflammatory Bowel Diseases: How, When, and for Whom?
    Wu JF
    Gut Liver; 2022 Jul; 16(4):515-524. PubMed ID: 34670875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease.
    Restellini S; Afif W
    J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33802816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proactive Therapeutic Drug Monitoring Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease Treated With Intravenous Vedolizumab.
    Porth R; Deyhim T; Zullow S; Rabinowitz LG; Grossberg LB; Roblin X; Paul S; Cheifetz AS; Papamichael K
    Inflamm Bowel Dis; 2024 Jul; ():. PubMed ID: 38953651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases.
    Papamichael K; Stocco G; Ruiz Del Agua A
    Ther Drug Monit; 2023 Oct; 45(5):579-590. PubMed ID: 37012629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proactive versus Reactive Therapeutic Drug Monitoring: Why, When, and How?
    Shmais M; Regueiro M; Hashash JG
    Inflamm Intest Dis; 2022 Jan; 7(1):50-58. PubMed ID: 35224018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-Tumor Necrosis Factor Alpha Therapeutic Drug Monitoring in Inflammatory Disease: A Systematic Review.
    Schneider C; Stratman S; Choragudi S; Lev-Tov H
    J Drugs Dermatol; 2023 May; 22(5):445-450. PubMed ID: 37133467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Drug Monitoring With Ustekinumab and Vedolizumab in Inflammatory Bowel Disease.
    Restellini S; Khanna R; Afif W
    Inflamm Bowel Dis; 2018 Sep; 24(10):2165-2172. PubMed ID: 29788272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology.
    Papamichael K; Cheifetz AS
    Curr Opin Rheumatol; 2020 Jul; 32(4):371-379. PubMed ID: 32412995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attitudes, perceptions and barriers in implementing therapeutic drug monitoring for anti-TNFs in inflammatory bowel disease: a survey from the Middle East.
    Nigam GB; Chatten K; Sharara A; Al-Taweel T; Alharbi O; Elamin H; Al Awadhi S; Annese V; Limdi JK
    Therap Adv Gastroenterol; 2024; 17():17562848241230902. PubMed ID: 38406794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases.
    Vande Casteele N; Herfarth H; Katz J; Falck-Ytter Y; Singh S
    Gastroenterology; 2017 Sep; 153(3):835-857.e6. PubMed ID: 28774547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proactive Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease.
    Roblin X; Riviere P; Flamant M; Veyrard P; Poullenot F; Paul S; Laharie D
    Inflamm Bowel Dis; 2018 Aug; 24(9):1904-1909. PubMed ID: 29726958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.